The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral Res. 2020 Apr 03;:104787
Authors: Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
PMID: 32251768 [PubMed - as supplied by publisher]